The Fly | MNKD

MannKind

· MNKD

Dashboard

Financials

Ratios

Transcripts

Valuation

Over a week ago

MannKind announces milestones in development of nintedanib DPI for IPF

MNKD

Jun 3, 6:11 AM

MannKind price target raised by $1 at Wells Fargo, here's why

MNKD

May 31, 9:08 PM

MannKind announces FDA approval of Afrezza for use in children aged 6 and older

MNKD

May 29, 12:31 PM

MannKind price target lowered by $1 at Mizuho

MNKD

May 7, 7:15 AM

MannKind price target raised by $2 at Wells Fargo, here's why

MNKD

May 7, 6:39 AM

MannKind price target raised by $2 at H.C. Wainwright, here's why

MNKD

May 7, 6:02 AM

MannKind reports Q1 EPS (2c), consensus 1c

MNKD

May 6, 4:32 PM

MannKind price target lowered by $2 at Mizuho, here's why

MNKD

Apr 13, 10:44 AM

MannKind price target lowered by $1 at Truist, here's why

MNKD

Apr 8, 8:27 AM

Theravance Biopharma price target raised by $3 at B. Riley, here's why

Apr 7, 8:27 AM

MannKind price target lowered by $2 at Wedbush, here's why

Mar 5, 8:59 AM

MannKind price target lowered by $1 at Wells Fargo, here's why

MNKD

Feb 27, 7:50 AM

MannKind price target lowered by $3 at H.C. Wainwright, here's why

MNKD

Feb 27, 7:09 AM

MannKind just downgraded at RBC Capital, here's why

Feb 27, 5:28 AM

MannKind reports Q4 EPS (5c) vs 3c last year

MNKD

Feb 26, 8:02 AM

RBC says United Therapeutics TreSMI presents 'material risk' to MannKind

Feb 25, 2:32 PM

Leerink sees MannKind selloff as 'overreaction' to headline news

Feb 25, 1:15 PM

H.C. Wainwright sees MannKind selloff 'potentially resetting' value proposition

Feb 25, 11:51 AM

United Therapeutics announces 'category killer product' Tresmi

Feb 25, 11:12 AM

MannKind sinks after United Therapeutics announces soft-mist inhaler

Feb 25, 11:08 AM

MannKind says first patient enrolled in INHALE-1ST study of Afrezza

MNKD

Feb 9, 6:06 AM

Morning Movers: USA Rare Earth surges after government funding pact

Jan 26, 8:55 AM

MannKind receives FDA approval for Afrezza dosage label

MNKD

Jan 26, 6:11 AM

MannKind shares not pricing in 'multiple tailwinds,' says H.C. Wainwright

MNKD

Jan 8, 12:03 PM

MannKind provides business updates, 2026 growth drivers

MNKD

Jan 8, 8:45 AM

Unique Inhaled Delivery Platform: The proprietary Technosphere technology enables rapid, non-injectable systemic delivery of therapeutic peptides and proteins, differentiating its products from conventional treatments.

FDA-Approved Inhaled Insulin Product: Afrezza is a unique, commercially available rapid-acting inhaled insulin, offering a distinct alternative for diabetes management to patients averse to injections.

Proprietary Manufacturing Expertise: MannKind possesses specialized manufacturing capabilities and facilities for its Technosphere platform, providing control over production and quality for its current and pipeline products.

Afrezza Commercialization Challenges and Sales Growth Limitations: MannKind's primary revenue source, Afrezza, faces ongoing challenges in achieving significant market penetration and sustained sales growth due to factors such as physician adoption, patient adherence, and competitive pressures.

Intense Competition in the Diabetes Treatment Market: The diabetes treatment market is highly competitive, with numerous established pharmaceutical companies offering a wide range of insulin products, oral medications, and other therapies, potentially limiting Afrezza's market share and pricing power.

Dependence on a Single Core Product and Platform: A substantial portion of MannKind's current and future success hinges on Afrezza and the Technosphere inhalation platform; failure to expand Afrezza's utility or successfully develop additional products using the platform could severely impact the company.